- Home
- / PrimeCell Bioscience
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
PrimeCell Bioscience financials data including stock price, CreditSafe score, income statement, and balance sheet.
Revenue
KČ26.6 M
FY, 2018
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CZK | FY, 2017 | FY, 2018 |
|---|---|---|
| Revenue | 28.0M | 26.6M |
| Revenue growth, % | -4.9% | |
| Cost of goods sold | 8.7M | 10.1M |
| Gross profit | 19.3M | 16.6M |
| Gross profit margin, % | 69.0% | 62.3% |
| General and administrative expense | 594.0K | 800.0K |
| Operating expense total | 21.4M | 20.3M |
| EBIT | (80.0K) | (3.6M) |
| EBIT margin, % | -0.3% | -13.6% |
| Interest income | 1.7M | 3.1M |
| Interest expense | 532.0K | 1.4M |
| Pre tax profit | 975.0K | (2.0M) |
| Net Income | 975.0K | (2.0M) |